ArticlebioRxiv : the preprint server for biology2026
Activation of Pol theta-mediated end joining begins during mitotic commitment.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Polymerase theta-mediated end-joining (TMEJ) is a salvage DNA repair pathway that anneals and ligates microhomologies flanking a DNA double-strand break (DSB) downstream of aborted homologous recombination to ensure DSBs are resolved before chromosome segregation. Here, we use a sensitive deep-sequencing approach to identify DSB repair outcomes at an endogenous locus. We observe that TMEJ is impaired by depletion or inhibition of DNA2, a component of the DSB resection machinery. Mechanistically we find that DNA2 deficiency influences TMEJ efficiency by slowing S-phase progression, thereby preventing cells from reaching mitotic commitment at the G2/M transition, when we find that TMEJ is optimally licensed to occur. Further interrogation of the cell cycle regulation of TMEJ reinforces a strict requirement for the mitotic kinase PLK1 in enabling TMEJ at the G2/M transition. We surprisingly find CDK1 to be largely dispensable for TMEJ, but important for a small subset of repair events likely occurring in mitosis. These findings have important implications for modulation of TMEJ in response to cell cycle kinase inhibitors that are in active development as anti-tumor agents.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.